ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

The U.S. Patent and Trademark Office has a history of attempting to challenge judicial decisions that the Office, usually for its own policy ...

Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

As LB Pharmaceuticals enters a pivotal stage of growth, the additions of Gad and Richard to our leadership team reinforce our ability to execute on our ambitious clinical and regulatory goals,” said ...

近日，艾伯维公布了2024全年及第四季度财报，数据显示，其全年总营收达563.34亿美元，以强劲势头为2025年的持续增长奠定了坚实基础。在面临修美乐专利悬崖的挑战时， ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro and Zepbound.

AbbVie Inc. ABBV reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.